- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
Washington, DC -- Medical marijuana advocates Americans for Safe Access (ASA) issued a report today that analyzes the Obama Administration's latest enforcement guidelines for federal prosecutors in states that regulate medical marijuana distribution. The report, "Third Time the Charm? State Laws on Medical Cannabis Distribution and Department of Justice Guidance on Enforcement," shows that states have already enacted regulations that meet federal concerns, and some would have stronger regulations if it were not for federal threats that disrupted the legislative process. The report concludes with recommendations for how federal and state legislators can protect patients and harmonize state and federal policies.
Medical marijuana patients greeted the Department of Justice (DOJ) memo issued August 31st by U.S. Deputy Attorney General James Cole with cautious optimism. The memo is the third from the Obama Administration that attempts to rein in federal prosecutors in states that allow for regulated distribution of marijuana. The first memo, issued in October 2009 by Cole's predecessor, then-Deputy Attorney General David Ogden, did not stop various federal prosecutors from attempting to thwart the implementation of several state medical marijuana laws. A report issued by ASA earlier this year put the cost of federal interference with state medical marijuana programs at more than $300 million.
“We hope the latest federal policy on marijuana will compel the Obama Administration to make good on its promises to stop wasting taxpayer money on undermining duly enacted state laws,” said ASA Executive Director Steph Sherer. “With almost 40 percent of Americans living in states that permit medical marijuana, it's time for the federal government to resolve the conflict between its outdated policies and the growing number of compassionate state laws.”
The ASA report released today is not an endorsement of the latest DOJ guidelines. "Non-binding memos are not the solution," the report says. "As patient advocates, we are hopeful that this latest policy will act as a stepping-stone for change in federal law and facilitate states enacting laws that regulate medical cannabis while serving the needs of their patient populations." In the meantime, advocates argue that by default the federal government should defer to local or state officials if violations of the law occur.
The ASA report recommends that state legislators use the 2013 Cole memo as a guide when developing production and distribution regulations, while avoiding unnecessarily restrictive policies that fail to meet the needs of patients. The report also urges lawmakers to recognize that all three DOJ directives maintain that cultivation by individual patients is not a federal enforcement concern, giving the green light for state legislators to preserve or adopt patient cultivation rules.
The report also recommends that Congress make short and long-term policy changes to ensure respect for state laws and protection for patients and their providers. The report urges federal legislators to restrict how DOJ funds are spent on enforcement in medical marijuana states until the DOJ can determine what "metrics" to use in evaluating compliance with their enforcement priorities. As a long-term solution, the report asks Congress to adopt HR 689, which would reclassify marijuana for medical use.
ASA report, "Third Time the Charm? State Laws on Medical Cannabis Distribution and Department of Justice Guidance on Enforcement:"
# # #